← Back to Patent Explorer
US5510105A Expired / Lapsed US ⏱️ 0.0 years remaining

Treatment of autoimmune diseases with IL-2 receptor-specific cytotoxins

Assignee: Beth Israel Deaconess Medical Center
•
Filing: 1994-07-08
•
Granted: 1996-04-23
•
Expires: 2014-07-08
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A method of treating a mammal suffering from an autoimmune disease state is provided. The method comprises administering to the mammal a cytotoxin-conjugated IL-2 receptor-specific substance during a proliferative burst of IL-2 receptor-bearing lymphocytes associated with the disease state, whereby the lymphocytes undergoing the proliferative burst are selectively killed.

Inventors

  • 👤 Terry B. Strom

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-02 12:32
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/2866; A; A61; A61P; A61P35/00; A61P37/00; A61P37/02; A61P37/06; A61K; A61K39/00; A61K2039/505; A61K38/00

Claims Analysis

Total Claims: 12
Claim 1
Independent Claim 56 words
A method of treating a mammal suffering from an autoimmune disease state-producing immune response characterized by a proliferative burst of IL-2 receptor-bearing lymphocytes, said method comprising administering to said mammal during said proliferative burst, a cytotoxin linked to an IL-2 receptor-specific substance whereby said IL-2 receptor-bearing lymphocytes are killed to the exclusion of non-IL-2 receptor-bearing cells.
Claim 2
Independent Claim 56 words
A method of treating a mammal suffering from an autoimmune disease state-producing immune response characterized by a proliferative burst of IL-2 receptor-bearing lymphocytes, said method comprising administering to said mammal during said proliferative burst, a cytotoxin linked to an IL-2 receptor-specific substance whereby said IL-2 receptor-bearing lymphocytes are killed to the exclusion of non-IL-2 receptor-bearing cells.
Claim 3
Dependent Claim 11 words
The method of claim 1, wherein said cytotoxin is diphtheria toxin.
Claim 4
Dependent Claim 10 words
The method of claim 1, wherein said cytotoxin is ricin.
Claim 5
Independent Claim 18 words
The method of any one of claims 1, 2 or 3, wherein the IL-2 receptor-bearing lymphocytes are T-lymphocytes.
Claim 6
Dependent Claim 13 words
The method of claim 4, wherein the auto immune disease is multiple sclerosis.
Claim 7
Dependent Claim 13 words
The method of claim 5, wherein the IL-2 receptor specific substance is IL-2.
Claim 8
Dependent Claim 13 words
The method of claim 4, wherein the IL-2 receptor specific substance is IL-2.
Claim 9
Independent Claim 18 words
The method of any one of claims 1, 2 or 3, wherein the IL-2 receptor-bearing lymphocytes are B-lymphocytes.
Claim 10
Dependent Claim 14 words
The method of claim 8, wherein the auto immune disease is systemic lupus erythematosus.
Claim 11
Dependent Claim 14 words
The method of claim 9, wherein the IL-2 receptor specific substance is IL- 2.
Claim 12
Dependent Claim 13 words
The method of claim 8, wherein said IL,-2 receptor specific substance is IL-2.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1999-04-23 1999-10-23 2000-04-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2003-04-23 2003-10-23 2004-04-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2007-04-23 2007-10-23 2008-04-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag